We report here the identification and characterization of a new platelet alloantigen, Duva+, implicated in a case of neonatal thrombocytopenia. Immunochemical studies demonstrated that the epitope was localized on glycoprotein (GP) IIIa. Sequencing of the exons 2 to 15 of GP IIIa gene polymerase chain reaction products from both parents revealed a single base substitution 517C>T (complementary DNA) present in a heterozygous state in DNA from the father leading to amino acid substitution Thr140Ile (ACC>ATC) within the Arg-Gly-Asp binding domain of GP IIIa. Flow cytometry and immunoprecipitation studies of IIb-C517 or T517 IIIa transfected Cos cells allowed us to demonstrate this mutation was responsible for expression of the Duva+epitope. By polymerase chain reaction–single-strand conformational-polymorphism analysis, the mutated allele could not be detected in a population of 100 healthy unrelated donors, indicating a low frequency of occurrence. The Thr140/Ile dimorphism, localized 3 amino acids upstream from the Arg143 involved in the expression of HPA-4a, did not interfere with the binding of an anti–HPA-4a antibody in flow cytometry. Results of functional analysis of wild-type or mutated transfected CHO cells—(1) aggregation in the presence of Ca++ and soluble fibrinogen after complex activation by dithiothreitol, (2) adhesion on coated fibrinogen, (3) binding of monoclonal antibody PAC-1 or LIBS antibody D3, and (4) outside-in signaling—all suggest that the Thr140Ile polymorphism localized in the Arg-Gly-Asp binding domain of GP IIIa does not affect significantly, if at all, the integrin function. We have shown that the anti-Duva+ antibody may inhibit platelet GP IIb-IIIa function.

The platelet membrane glycoprotein (GP) IIb-IIIa complex or αIIbβ3 belongs to the integrin family of heterodimeric adhesion receptors involved in cell-matrix and cell-cell interactions.1 This complex can bind ligands containing the Arg-Gly-Asp (RGD) sequence, such as fibrinogen, von Willebrand factor, vitronectin, and fibronectin. It plays a major role in platelet aggregation by interacting with the C-terminal part of the γ chain of fibrinogen.2,3 The genes coding for GP IIb and GP IIIa are highly polymorphic. Most of the human platelet alloantigen (HPA) systems described are carried by the GP IIb-IIIa complex, and most of them are localized on the GP IIIa subunit: HPA-1, -4, -6, -7, -8, -10, -11, and one unclassified private antigen Oea.4-11 Only 2 of the platelet antigen systems, HPA-3 and -9, reside on GP IIb,12,13 and the genetic origin of the Vaa antigen remains to be determined.14 These antigenic systems result from a single base-pair substitution with the exception of Oea, which depends on an in-frame deletion of 3 bases.11 Platelet alloantigen systems are involved in neonatal alloimmune thrombocytopenia (NAIT), posttransfusion purpura, and refractoriness to platelet transfusions. NAIT is characterized by the destruction of fetal or newborn platelets by a maternal antibody elicited by the maternofetal platelet antigen incompatibility. During the course of the severe thrombocytopenia in the fetus or the newborn, there is a risk of intracerebral hemorrhage leading to death or neurologic impairment. The incidence of NAIT has been shown to be 1 per 800 to 1000 live births.15 Most NAIT in Caucasians involves HPA-116 or HPA-517 (GP Ia polymorphism18) maternofetal incompatibilities.

We describe here a case of severe NAIT due to a new alloantigen Duva+ localized on GP IIIa. The genetic determination revealed a single base-pair substitution, C>T, at the GP IIIa complementary DNA (cDNA) position 517. This leads to a threonine/isoleucine dimorphism at position 140 of the mature GP IIIa. The Duva+ form of the GP IIb-IIIa complex expressed in Cos cells shows this polymorphism is responsible for the alloimmunization and the consequent NAIT. The Duva+ polymorphism that was localized in the RGD binding site of GP IIIa could affect the αIIbβ3 function. Because no individuals homozygous for Duva+ were available, stable cell lines expressing the Duva+ form of GP IIb-IIIa were produced to study a possible effect of the Duva+ substitution on integrin function.

Case report

We report a 30-year-old white woman (Duv), para 4, gravida 4, who gave birth to a full-term male child with a severe thrombocytopenia at birth (platelets 17 × 109/L) associated with minor bruises and petechiae. The child was otherwise healthy (Apgar score 9 of 10). He was treated with a total of 1.6 g/kg intravenous immunoglobulin G (IgG) over 24 hours. On day 3, the platelet count had increased to 139 × 109/L, and the outcome was favorable. Neonatal thrombocytopenia was not recorded in any of the siblings.

Blood samples

Blood samples from the mother, the father, the infant, and healthy adult human volunteers were collected by venipuncture using 5 mM ethylenediaminetetraacetic acid as an anticoagulant. Samples were not available from the siblings. Platelets were separated by differential centrifugation and stored until use at 4°C in isotonic solution containing 0.1% sodium azide.

Platelet serology

Characterization of the maternal serum alloantibody and platelet phenotyping were performed with the monoclonal antibody–specific immobilization of platelet antigen assay (MAIPA).19 The following monoclonal antibodies (Moabs) were used: Gi9 to GP Ia and B1G6 to the β2-microglobulin (Immunotech, Marseille, France), Pl1-64 and Pl2-46 to GP IIb-IIIa (from the authors' laboratory), and GR-P to GP Ib-IX (from Dr Garrido, Granada, Spain). A serum containing an anti–HPA-1a alloantibody from a case of NAIT was used as a positive control for the GP IIb-IIIa complex.

Isolation of genomic DNA

Genomic DNA was isolated from peripheral blood according to published procedures.20 

Genotyping

Genotyping was performed by polymerase chain reaction (PCR)–sequence-specific primers for the HPA-1, -3, and -4 systems21 and by PCR–restriction fragment length polymorphism for the HPA-5, -6, -7, -9, -10 and -11 systems.7,9,13,22,23 

Western blot analysis

The Western blot procedure was used as previously described.24 

Sequencing and SSCP analysis

The exons 2 to 15 of the gene coding for GP IIIa were amplified and sequenced as previously described.25 Single-strand conformational polymorphism (SSCP) analysis was performed according to the previously published procedure.25 

Site-directed mutagenesis

The mutation Duv was introduced into wild-type GP IIIa cDNA cloned in the eukaryotic expression vector by using the GeneEditor in vitro mutagenesis system (Promega, Lyon, France) according to the manufacturer's instructions. We used the mutagenic oligonucleotide 5′-GCTTTCGCATCTGGATGGCCAGCTTGGTAC-3′, where the underlined “A” replaced a “G” in the wild-type sequence.26The presence of the mutation was confirmed by sequencing the region of interest.

Cell culture/transfection

Cos-7 cells were cultivated in Iscoves Dulbecco modified Eagle medium supplemented with 10% fetal calf serum and 1% antimycotic/antibiotic reagent (Life Technologies, Cergy-Pontoise, France) in a 5% CO2 saturating-humidity atmosphere. Petri dishes (10 cm) were seeded with 1.5 × 106 cells and incubated for 12 hours. Cells rinsed with phosphate-buffered saline (PBS) were transfected by incubation at 37°C for 5 hours in 3 mL Opti-MEM containing 5 μg of the pcDNA3 plasmid containing IIb cDNA and 5 μg of the pcDNA3 plasmid containing IIIa cDNA (from Dr P. J. Newman, The Blood Research Institute, The Blood Center of Southeastern Wisconsin, Milwaukee, WI) and 40 μL Lipofectamine (Life Technologies). The incubation was continued overnight after adding 15 mL complete medium with 20% fetal calf serum. The medium was replaced by 15 mL medium supplemented with 10% fetal calf serum and the culture incubated for an additional 48 hours before transfected cells were harvested by using trypsin–ethylenediaminetetraacetic acid (Life Technologies). Cells were washed 3 times, resuspended in PBS (108/mL), and kept on ice until used.

For stable expression, CHO cells were transfected with 2 μg of each plasmid and 20 μL Lipofectamine according to the procedure described above. Forty-eight hours after transfection the cells were subjected to drug selection in media containing 800 μg/mL G 418 (Genecitin, Life Technologies) for 10 days. Resistant cells expressing the GP IIb-IIIa complex were isolated by using the anticomplex-specific Moab AP-2 (GTI, Brookfield, WI) and the Dynabeads M-450 GAM IgG system (Dynal, Bromborough, United Kingdom) according to the manufacturer's instructions. After cloning, stable cell lines were selected by flow cytometric analysis on their ability to bind the anti-GP IIb-IIIa Moab AP-2.

Flow cytometry

Surface expression and fibrinogen binding function of the transfected cells were analyzed by flow cytometry. For each analysis, 5 × 105 cells were incubated in 100 μL PBS containing 4 mg/mL bovine serum albumin (BSA) and 30 μL human sera or 1 μg/mL purified Moabs SZ 22 to GP IIb, SZ 21 to GP IIIa (Immunotech), D3 to a ligand-induced binding site (LIBS) GP IIIa epitope (from Dr L. Jennings, Memphis, TN), or the 1:1000 diluted AP-3 (anti-GP IIIa) and AP-2 ascites (GTI). Cells were incubated for 30 minutes at room temperature before being washed twice in 3 mL PBS-BSA. They were resuspended in 100 μL PBS-BSA containing a 1:50 dilution of R-phycoerythrin–conjugated goat antihuman or antimouse IgGs (Fc-specific) (Immunotech). Cells were incubated for 30 minutes, washed twice, and analyzed on a FACSCalibur flow cytometer (Becton Dickinson, Le Pont de Claix, France).

For binding analysis of the fibrinogen and the ligand mimetic Moab PAC-1 (Becton Dickinson), cells were treated by dithiothreitol (DTT) in Tyrode buffer as described in Lyman et al27 to “activate” the GP IIb-IIIa complex receptor function. A total of 106 treated or untreated cells were incubated in 100 μL Tyrode solution containing 200 μg/mL fibrinogen conjugated to the fluorochrome A-488 (Molecular Probes, Eugene, OR), 2 mM CaCl2, and 4 mg/mL BSA for 20 minutes at room temperature. Cells were washed once and resuspended in 500 μL Tyrode solution containing BSA and calcium prior to being analyzed by flow cytometry. PAC-1 binding was analyzed as previously described by using a R-phycoerythrin–conjugated polyclonal goat antimouse IgM (Immunotech). In some experiments the complex was “activated” by incubating transfected cells with 200 μg/mL of the anti-LIBS Moab D3.28 

Inhibition of the anti-Duva+ alloantibody binding to transfected cells by the Arg-Gly-Asp-Ser (RGDS) or the Arg-Gly-Glu-Ser (RGES) peptides was studied by flow cytometry. For each analysis, 2.5 × 105 cells were incubated for 30 minutes at 4°C in 100 μL PBS containing 2% BSA, 100 mM MgCl2, 100 mM CaCl2, and 25 mM RGDS or RGES peptides prior the addition of 10 μL of the maternal or a control serum. Cells were incubated for 90 minutes at 4°C before being washed and analyzed as described above.

Cell aggregation and adhesion

Cell aggregation and adhesion experiments were performed as described by Lyman et al27 with a single modification for adhesion tests: 96-well culture plates were coated with 50 μL PBS containing different concentrations of fibrinogen or BSA or 20 μg/mL AP-2.

In inhibition experiments, prior to performing adhesion tests, cells were incubated for 30 minutes at room temperature with either 20 μg/mL of the anti-GP IIb-IIIa Moab AP-2 or a nonrelevant polyclonal mouse IgG, or with 5 mM of the RGDS or the RGES peptides. In these experiments, microtiter plates were coated by 20 μg/mL fibrinogen.

To assess the effect of the anti-Duva+ antibody on cell adhesion, cells were incubated with 30 μL human sera for 90 minutes at 4°C prior to plating onto wells coated with 250 ng fibrinogen or BSA. Human sera used in these experiments were incubated for 1 hour at room temperature with CHO cells expressing wild-type GP IIb-IIIa to minimize nonspecific binding in subsequent adhesion assays.

Tyrosine phosphorylation of the focal adhesion kinase

Tyrosine phosphorylation and focal adhesion kinase (pp125FAK) immunoprecipitation assays were performed according to Schaffner-Reckinger et al.29Western blotting was performed as previously described24except that saturation and Moab incubation steps were performed in buffer II (10 mM Tris-HCl pH 7.5, 100 mM NaCl, 0.1% Tween 20) containing 1% BSA. Washing steps were performed in buffer II alone. The pp125FAK and phosphotyrosine were detected, respectively, by using a Moab to the pp125FAK and the Moab PY-20 (Transduction Laboratory, Lexington, KY) diluted 1:1000. Blots probed with the Moab PY-20 were stripped for 30 minutes at 50°C in 62.5 mM Tris-HCL (pH 6.7), 2% sodium dodecyl sulfate (SDS), and 100 mM β-mercaptoethanol before being probed with the Moab directed against the pp125FAK. Blot densitometric analysis was performed to compare the phoshorylation percentage of the different transfected cell types with regard to their adherent or nonadherent status. For each cell type, the phosphorylation percentage is expressed as the difference between ratios obtained for adherent (A) and nonadherent (S) cells as follows:

Phosphorylation%=BI(P­Tyr)BI(FAK)ABI(P­Tyr)BI(FAK)SBI(P­Tyr)BI(FAK)A×100
(BIband intensity)

Serologic studies

The maternal serum was tested against the paternal platelets and a panel by the MAIPA assay. The maternal serum gave a selective and strong positive reaction with the father's platelets in MAIPA using the Moab Pl1-64 directed against the GP IIb-IIIa complex (Figure1A). Results were negative with Moabs against other membrane GPs (Ia-IIa, Ib-IX, or HLA). No positive reaction was observed with the panel regardless of the Moab used in the reaction and the platelet alloantigenic status despite incompatibility in the HPA-3 system between the mother and the father or the child (Table 1). No autoantibodies were identified that reacted with the father's or mother's platelets. Moreover, genotypes of both parents did not show any incompatibility in the HPA-4 and the HPA-6w to -11w alloantigenic systems (excluding HPA-8w, which was not tested) (Table 1). These results were in favor of a new platelet alloantigen localized on the GP IIb-IIIa complex.

Fig. 1.

Identification and characterization of the anti-Duva+ antibody by the techniques of MAIPA and Western blot.

(A) The reactivity of the serum Duv was tested in MAIPA with the mother's platelets, 4 panel platelets, and the father's platelets by using the Moab Pl1-64 to capture the GP IIb-IIIa complex. Paternal autoantibodies were searched for by direct incubation of the platelets with the Moabs (Dir). (B) Immunoblot of SDS-soluble platelet proteins subjected to SDS–polyacrylamide gel electrophoresis under nonreduced conditions and transferred to nitrocellulose membrane. The maternal serum Duv was tested with father's platelets (lane 1), mother's platelets (lane 2), and a control donor (lane 3). An anti–HPA-1a serum (anti–GP IIIa) was used as positive control (lane 4). Human IgGs were revealed by using an antihuman IgG conjugated to the peroxidase associated to the chemiluminescence detection technique. The maternal serum Duv bound specifically to a protein migrating in the position of GP IIIa of the father's platelets.

Fig. 1.

Identification and characterization of the anti-Duva+ antibody by the techniques of MAIPA and Western blot.

(A) The reactivity of the serum Duv was tested in MAIPA with the mother's platelets, 4 panel platelets, and the father's platelets by using the Moab Pl1-64 to capture the GP IIb-IIIa complex. Paternal autoantibodies were searched for by direct incubation of the platelets with the Moabs (Dir). (B) Immunoblot of SDS-soluble platelet proteins subjected to SDS–polyacrylamide gel electrophoresis under nonreduced conditions and transferred to nitrocellulose membrane. The maternal serum Duv was tested with father's platelets (lane 1), mother's platelets (lane 2), and a control donor (lane 3). An anti–HPA-1a serum (anti–GP IIIa) was used as positive control (lane 4). Human IgGs were revealed by using an antihuman IgG conjugated to the peroxidase associated to the chemiluminescence detection technique. The maternal serum Duv bound specifically to a protein migrating in the position of GP IIIa of the father's platelets.

Close modal
Table 1.

HPA genotype of the Duv family

HPA
− 1− 3− 4− 6 to − 11*
Mother a/a a/a a/a a/a 
Father a/b a/b a/a a/a 
Child a/a a/b a/a NT 
HPA
− 1− 3− 4− 6 to − 11*
Mother a/a a/a a/a a/a 
Father a/b a/b a/a a/a 
Child a/a a/b a/a NT 

NT indicates not tested.

*

HPA-8 not tested.

Western blotting experiments were performed to identify the subunit that carried the Duva+ epitope. Maternal antibody reacted specifically with a protein migrating under nonreduced conditions in the position of GP IIIa (95 kd) of the father's platelets (Figure 1B, lane 1) identified by the reactivity of a well-characterized anti–HPA-1a antibody (Figure 1B, lane 4). The band at 150 kd detected in all lysates corresponds to platelet-associated IgG. These results were in favor of the localization of the putative antigen on GP IIIa. Disruption of disulfide bonds by DTT treatment of the lysates abolished the maternal antibody binding to GP IIIa. When paternal platelets were treated with α-chymotrypsin, the epitope carried on GP IIIa was no longer recognized by the maternal antibody (data not shown).

Genetic analysis

To identify the mutation responsible for the expression of this new antigen, genomic DNA from the father, the mother, and the child was amplified for all coding sequences of the GP IIIa gene. Each PCR product was directly sequenced by using an automatic DNA-analyzer system (AlF-Express, Amersham Pharmacia Biotech, Saclay, France). A single nucleotide change corresponding to a C>T mutation in a heterozygous state was identified in the exon 4 of the DNA from the father and his child (Figure2A). This C>T mutation localized at the position 517 of the cDNA leads to the Thr140Ile substitution in the peptide sequence of the mature GP IIIa. This mutation was confirmed by SSCP analysis showing an alteration of the migration profile of exon 4–PCR products from the father and child compared with the mother's (Figure 2B). The 3 profiles showed the presence of a common peak at 230 minutes that corresponds to the C allele, whereas an additional peak on the father and child profiles at 220 minutes revealed the C>T change in the nucleotide sequence. The presence of 2 peaks confirms the heterozygous state for the father and his child. This mutation was not identified in DNA from a population of 100 unrelated healthy donors using the SSCP technique (not shown).

Fig. 2.

Direct sequence analysis and SSCP profiles of amplified exons 4 of GP IIIa DNAs from the mother Duv, the father, and their child.

(A) The genomic DNA sequences corresponding to the region 512 to 522 of the GP IIIa cDNA are shown. The mother is homozygous for the C517 (underlined), and the father and the child are C/T heterozygous (Y). The C>T base change results in a Thr (ACC) for an Ile (ATC) substitution at the amino acid 140 of the mature GP IIIa. The polymorphic position is indicated by an arrow. (B) The interesting part of the SSCP profiles of the exon 4–PCR products obtained for the reverse DNA single strand at 20°C is shown. The peak detected at 230 minutes in the mother's profile corresponds to the C517 allele of the GP IIIa. The peak at 220 minutes obtained for the father and the child is specific for the T517 form. SSCP confirms the father and the child are heterozygous for the C>T mutation.

Fig. 2.

Direct sequence analysis and SSCP profiles of amplified exons 4 of GP IIIa DNAs from the mother Duv, the father, and their child.

(A) The genomic DNA sequences corresponding to the region 512 to 522 of the GP IIIa cDNA are shown. The mother is homozygous for the C517 (underlined), and the father and the child are C/T heterozygous (Y). The C>T base change results in a Thr (ACC) for an Ile (ATC) substitution at the amino acid 140 of the mature GP IIIa. The polymorphic position is indicated by an arrow. (B) The interesting part of the SSCP profiles of the exon 4–PCR products obtained for the reverse DNA single strand at 20°C is shown. The peak detected at 230 minutes in the mother's profile corresponds to the C517 allele of the GP IIIa. The peak at 220 minutes obtained for the father and the child is specific for the T517 form. SSCP confirms the father and the child are heterozygous for the C>T mutation.

Close modal

Link between the Thr140Ile mutation and the Duv alloimmunization

To study the role of the Thr140Ile polymorphism in neonatal thrombocytopenia, the allelic Duva+ form of the GP IIb-IIIa complex was reproduced in a mammalian cell transfection system. After transient transfection of GP IIb cDNA along with the wild-type (Duva−) or mutated (Duva+) GP IIIa cDNA, Cos cells were analyzed for the expression of the GP IIb-IIIa complex by flow cytometry using a panel of anti-GP IIb-IIIa Moabs (AP-2, AP-3, SZ 21, SZ 22). Both the Duva− and the Duva+allelic forms of the GP IIb-IIIa complex were expressed in approximately 30% of the transfected cells (data not shown). The flow cytometry histograms obtained with the Duva− and the Duva+ cells probed with an alloantiserum anti–HPA-1a (Figure 3A) or the maternal serum Duv (Figure 3B) showed that the maternal serum reacted selectively with the Duva+ cells, whereas anti–HPA-1a serum reacted with both cell types. Similar results were obtained by Western blot and immunoprecipitation assays (data not shown). These results demonstrated that the Thr140Ile substitution was responsible for the expression of the Duva+ epitope involved in the maternal alloimmunization.

Fig. 3.

Flow cytometric analysis of the maternal serum Duv binding with the Duva+ allelic form of the GP IIb-IIIa complex.

Cos cells expressing the Duva− or the Duva+form of the GP IIb-IIIa complex were incubated with a serum containing an anti–HPA-1a antibody (A) and with the maternal serum Duv (B) or an AB control serum (A and B, dotted line). Incubated cells were rinsed prior to incubation with an antihuman IgG conjugated to phycoerythrin. Washed cells were analyzed by a FACSCalibur cytometer. The maternal serum Duv reacts specifically with the cells expressing the Duva+ allelic form of the GP IIb-IIIa complex, whereas positive reaction was observed for both types of cells with anti–HPA-1a.

Fig. 3.

Flow cytometric analysis of the maternal serum Duv binding with the Duva+ allelic form of the GP IIb-IIIa complex.

Cos cells expressing the Duva− or the Duva+form of the GP IIb-IIIa complex were incubated with a serum containing an anti–HPA-1a antibody (A) and with the maternal serum Duv (B) or an AB control serum (A and B, dotted line). Incubated cells were rinsed prior to incubation with an antihuman IgG conjugated to phycoerythrin. Washed cells were analyzed by a FACSCalibur cytometer. The maternal serum Duv reacts specifically with the cells expressing the Duva+ allelic form of the GP IIb-IIIa complex, whereas positive reaction was observed for both types of cells with anti–HPA-1a.

Close modal

Effect of the Duva+ polymorphism on the reactivity of anti–HPA-4a antibody

The Thr140Ile substitution is localized to 3 amino acids upstream from the Arg143 involved in the expression of the HPA-4a antigen. To determine whether the Duva+ polymorphism could modify the antigenicity of the HPA-4a epitope, the binding of an anti–HPA-4a antibody to GP IIb–mutated GP IIIa Cos cells was studied by flow cytometry (Figure 4). The anti–HPA-4a antibody containing sera tested reacted to the same extent with both the wild-type or mutated cells. These results show the Thr140Ile substitution does not significantly affect the reactivity of the anti–HPA-4a antibody tested.

Fig. 4.

Flow cytometric analysis of the binding of an anti–HPA-4a antibody to the Duva+ allelic form of the GP IIb-IIIa complex.

Cos cells expressing the Duva− (white bar) or the Duva+(gray bar) forms of the GP IIb-IIIa or nontransfected (black bar) were incubated with an AB serum as control and a serum containing an anti–HPA-4a antibody. Human bound IgGs were detected by flow cytometry as described in the legend to Figure 3. The anti–HPA-4a antibody reacted with both types of cells independently of the allelic forms of the GP IIb-IIIa. The serum AB did not show any significant reactivity whatever the cell type tested. Results correspond to a mean of 3 experiments ± SD.

Fig. 4.

Flow cytometric analysis of the binding of an anti–HPA-4a antibody to the Duva+ allelic form of the GP IIb-IIIa complex.

Cos cells expressing the Duva− (white bar) or the Duva+(gray bar) forms of the GP IIb-IIIa or nontransfected (black bar) were incubated with an AB serum as control and a serum containing an anti–HPA-4a antibody. Human bound IgGs were detected by flow cytometry as described in the legend to Figure 3. The anti–HPA-4a antibody reacted with both types of cells independently of the allelic forms of the GP IIb-IIIa. The serum AB did not show any significant reactivity whatever the cell type tested. Results correspond to a mean of 3 experiments ± SD.

Close modal

Effect of the Thr140Ile mutation on the function of the integrin αIIbβ3

Fibrinogen and PAC-1 binding.

The Thr140Ile mutation is localized in the amino acid stretch Asp109 to Glu171 known to be a putative RGD binding site of the β3-subunit.30 To test the effect of this mutation on the integrin function—because no homozygous mutated platelets were available—stable cell lines expressing the Duva− and the Duva+ allelic forms of the GP IIb-IIIa complex were produced by cotransfection of GP IIb cDNA either with wild-type or mutated GP IIIa cDNA into CHO cells. Both allelic forms were able to bind to soluble fibrinogen (Figure5A) after DTT treatment in a similar manner, as shown by the increase in the mean fluorescence intensity, taking into account that the surface expression of the GP IIb-IIIa complexes on wild-type cells is slightly lower than for the mutated cells. This difference has been assessed by flow cytometry binding studies in saturation conditions of the Moabs directed against GP IIb-IIIa (AP-2) or GP IIIa (AP-3 and SZ 21) (data not shown). No binding occurred to nontransfected cells.

Fig. 5.

Analysis of the binding of soluble fibrinogen and of the Moab PAC-1.

CHO cells stably transfected and expressing the Duva− or Duva+ allelic forms of the GP IIb-IIIa were treated by 10 mM DTT (bold line) or buffer (dotted line) for 20 minutes prior to being incubated with 200 μg/mL fibrinogen-A488 (A) or with 1 μg/mL of the Moab PAC-1 (B). Washed cells were directly analyzed for the fibrinogen binding by flow cytometry or incubated with an IgG anti-IgM conjugated to phycoerythrin to detect PAC-1 binding and analyzed. The Duva+ form of GP IIIa did not impair fibrinogen or PAC-1 binding to the complex.

Fig. 5.

Analysis of the binding of soluble fibrinogen and of the Moab PAC-1.

CHO cells stably transfected and expressing the Duva− or Duva+ allelic forms of the GP IIb-IIIa were treated by 10 mM DTT (bold line) or buffer (dotted line) for 20 minutes prior to being incubated with 200 μg/mL fibrinogen-A488 (A) or with 1 μg/mL of the Moab PAC-1 (B). Washed cells were directly analyzed for the fibrinogen binding by flow cytometry or incubated with an IgG anti-IgM conjugated to phycoerythrin to detect PAC-1 binding and analyzed. The Duva+ form of GP IIIa did not impair fibrinogen or PAC-1 binding to the complex.

Close modal

The binding of the ligand mimetic Moab PAC-131 was also analyzed in regard to the Duva+ polymorphism (Figure 5B). Results show that the PAC-1 antibody binds to both allelic forms of the GP IIb-IIIa complex in an activation-dependent manner. No binding was observed to nontransfected cells in the same conditions. Furthermore, the PAC-1 Moab bound similarly to GP IIb-IIIa activated by the anti-LIBS Moab D3 (not shown).

Aggregation.

Soluble fibrinogen-dependent aggregation of both types of transfected cells was investigated following DTT treatment. Both cells expressing the Duva− and Duva+ allelic forms of the GP IIb-IIIa complex were able to form large aggregates (Figure6). Under the same experimental conditions, nontransfected cells did not aggregate.

Fig. 6.

Aggregation of transfected CHO cells.

Cells not transfected (NT) or expressing the Duva− or Duva+ allelic forms of the GP IIb-IIIa were treated by 10 mM DTT (+DTT) for 20 minutes at room temperature to activate the complex prior to being incubated with 100 μg/mL fibrinogen in the presence of 2 mM calcium with gentle shaking for 20 minutes. Only Duva− and Duva+ cells aggregated in the presence of fibrinogen when treated by DTT. No significant aggregation was observed for nontreated cells (−DTT) or nontransfected cells treated or not. The specimens were examined with a Leica-Orthoplan fluorescence microscope (Leica, Wetzlar, Germany) using a ×40 oil immersion objective. Microphotographs were taken using Ilford HP5 400 films (ILFORD Imaging, Mobberley, Cheshire, United Kingdom).

Fig. 6.

Aggregation of transfected CHO cells.

Cells not transfected (NT) or expressing the Duva− or Duva+ allelic forms of the GP IIb-IIIa were treated by 10 mM DTT (+DTT) for 20 minutes at room temperature to activate the complex prior to being incubated with 100 μg/mL fibrinogen in the presence of 2 mM calcium with gentle shaking for 20 minutes. Only Duva− and Duva+ cells aggregated in the presence of fibrinogen when treated by DTT. No significant aggregation was observed for nontreated cells (−DTT) or nontransfected cells treated or not. The specimens were examined with a Leica-Orthoplan fluorescence microscope (Leica, Wetzlar, Germany) using a ×40 oil immersion objective. Microphotographs were taken using Ilford HP5 400 films (ILFORD Imaging, Mobberley, Cheshire, United Kingdom).

Close modal

Adhesion.

The functionality of the Duva+ allelic form of the GP IIb-IIIa complex was also analyzed in regard to its capacity to bind fibrinogen immobilized on plastic. Both wild-type or mutated GP IIIa CHO cells adhered to immobilized fibrinogen in a similar dose-dependent manner (Figure 7). This adhesion is mediated specifically by the GP IIb-IIIa complex because the incubation with anti–GP IIb-IIIa Moab AP-2 (20 μg/mL) prior to adhesion inhibited the cell attachment32 by 42% and 47% of their respective capacities (Figure 8A, white bars). A polyclonal mouse IgG used as control did not inhibit cell attachment (Figure 8A, gray bars).

Fig. 7.

Adhesion of transfected CHO cells onto immobilized fibrinogen.

Transfected cells expressing the Duva+ or the Duva− forms of the GP IIb-IIIa complex were incubated for 2 hours at 37°C in microtiter plates coated with different concentration of fibrinogen, BSA, or 20 μg/mL of the anti-GP IIb-IIIa Moab AP-2. Nonadherent cells were removed by washing, and adherent cells were fixed and stained in a crystal-violet solution for 30 minutes at room temperature. After washing and cell lysis in SDS, absorbance was measured at 560 nm. Cell adhesion was normalized to cell adhesion on AP-2 (fibrinogen/AP-2 ratio). Both cell types adhere onto fibrinogen in a dose-dependent manner. Results represent the mean ± SD of 3 experiments.

Fig. 7.

Adhesion of transfected CHO cells onto immobilized fibrinogen.

Transfected cells expressing the Duva+ or the Duva− forms of the GP IIb-IIIa complex were incubated for 2 hours at 37°C in microtiter plates coated with different concentration of fibrinogen, BSA, or 20 μg/mL of the anti-GP IIb-IIIa Moab AP-2. Nonadherent cells were removed by washing, and adherent cells were fixed and stained in a crystal-violet solution for 30 minutes at room temperature. After washing and cell lysis in SDS, absorbance was measured at 560 nm. Cell adhesion was normalized to cell adhesion on AP-2 (fibrinogen/AP-2 ratio). Both cell types adhere onto fibrinogen in a dose-dependent manner. Results represent the mean ± SD of 3 experiments.

Close modal
Fig. 8.

Inhibition of the transfected cell adhesion by the Moab AP-2 or the peptide RGDS.

Transfected cells expressing the Duva+ or the Duva− forms of the GP IIb-IIIa complex were incubated in microtiter plates coated with 20 μg/mL fibrinogen. The incubation was performed in PBS-albumin (control) and in the presence of 20 μg/mL of either the Moab AP-2 or a nonrelevant polyclonal mouse IgG (A) or in the presence of 5 mM of the RGDS or RGES peptides (B). Quantification of bound cells was performed as described in the legend to Figure 7. The adhesion of CHO cells expressing the Duva+ GP IIIa form of the complex is inhibited by the Moab AP-2 or the peptide RGDS. Results represent the mean ± SD of 3 experiments.

Fig. 8.

Inhibition of the transfected cell adhesion by the Moab AP-2 or the peptide RGDS.

Transfected cells expressing the Duva+ or the Duva− forms of the GP IIb-IIIa complex were incubated in microtiter plates coated with 20 μg/mL fibrinogen. The incubation was performed in PBS-albumin (control) and in the presence of 20 μg/mL of either the Moab AP-2 or a nonrelevant polyclonal mouse IgG (A) or in the presence of 5 mM of the RGDS or RGES peptides (B). Quantification of bound cells was performed as described in the legend to Figure 7. The adhesion of CHO cells expressing the Duva+ GP IIIa form of the complex is inhibited by the Moab AP-2 or the peptide RGDS. Results represent the mean ± SD of 3 experiments.

Close modal

The peptide RGDS (5 mM), a potent inhibitor of the platelet aggregation and adhesion mediated by the GP IIb-IIIa/fibrinogen interaction,33 inhibited the binding of both transfected cells (Figure 8B, white bars) to fibrinogen when compared with the results obtained either in the absence of peptide (black bars) or in the presence of 5 mM of the noninhibitory control peptide RGES (gray bars).

These results show that the Duva+ mutation does not impair the binding of the GP IIb-IIIa complex onto immobilized fibrinogen.

Outside-in signaling properties.

The oligomerization of GP IIb-IIIa complexes during platelet adhesion on immobilized fibrinogen leads to an outside-in signaling responsible for the autophosphorylation of pp125FAK. This outside-in signaling function documented in CHO cells expressing GP IIb-IIIa27 was evaluated in regard to the Duv polymorphism. As shown in Figure 9A, significant pp125FAK phosphorylation was observed in both adherent (Adh.) transfected CHO cell lines expressing either the wild-type or mutated GP IIIa but not in nonadherent (Susp.) cells. The phosphorylation levels expressed as phosphorylation percentage were similar for both cell types (Figure 9B).

Fig. 9.

Phosphorylation of pp125FAK.

CHO cells expressing the Duva+ or the Duva−forms of the GP IIb-IIIa complex were layered onto immobilized fibrinogen (Adh.) or maintained in suspension (Susp.) for 2 hours at 37°C before the cells were lysed and the pp125FAKimmunoprecipitated. (A) Blots were performed to detect phosphotyrosine (blots P-tyr) and the pp125FAK (blots FAK) by using the PY-20 and an anti-pp125FAK Moabs, respectively. Detection was performed by using an antimouse IgG conjugated to the peroxidase associated to a chemiluminescent detection system. (B) The histogram represents the mean phosphorylation percentage for each cell line, calculated from the band intensities measured by densitometric analysis (see “Materials and methods”). Results represent the mean ± SD of 3 experiments.

Fig. 9.

Phosphorylation of pp125FAK.

CHO cells expressing the Duva+ or the Duva−forms of the GP IIb-IIIa complex were layered onto immobilized fibrinogen (Adh.) or maintained in suspension (Susp.) for 2 hours at 37°C before the cells were lysed and the pp125FAKimmunoprecipitated. (A) Blots were performed to detect phosphotyrosine (blots P-tyr) and the pp125FAK (blots FAK) by using the PY-20 and an anti-pp125FAK Moabs, respectively. Detection was performed by using an antimouse IgG conjugated to the peroxidase associated to a chemiluminescent detection system. (B) The histogram represents the mean phosphorylation percentage for each cell line, calculated from the band intensities measured by densitometric analysis (see “Materials and methods”). Results represent the mean ± SD of 3 experiments.

Close modal

Effect of the anti-Duva+ antibody on cell adhesion onto fibrinogen

The effect of the anti-Duva+ antibody on adhesion was studied by using transfected cells in an adhesion test because no homozygous Duva+ platelets were available for aggregation studies. CHO cells expressing the Duva+ form of the GP IIb-IIIa complex were incubated with a saturating amount of the anti-Duva+ antibody and analyzed for their adhesion capacity onto fibrinogen (Figure 10A). The anti-Duva+ antibody inhibited cell adhesion to 67.5%, whereas the AB serum used as a control did not show a significant inhibitory effect (4.5%).

Fig. 10.

Cell adhesion inhibition and the anti-Duva+antibody.

(A) CHO cells expressing the Duva+ form of the complex were incubated with the anti-Duva+ (open bar) or a control (gray bar) sera. Washed cells were then layered onto immobilized fibrinogen (250 ng per well) for 2 hours at 37°C. Quantification of bound cells was performed as described in the legend to Figure 7. (B) CHO cells expressing the Duva+ form of the complex were incubated with RGDS (open bar) or a control RGES (gray bar) peptides prior to adding 10 μL anti-Duva+ sera corresponding to a half-saturation amount. After a washing, bound human antibodies were detected by flow cytometry as described in the legend to Figure 3. Results represent the mean ± SD of 3 experiments.

Fig. 10.

Cell adhesion inhibition and the anti-Duva+antibody.

(A) CHO cells expressing the Duva+ form of the complex were incubated with the anti-Duva+ (open bar) or a control (gray bar) sera. Washed cells were then layered onto immobilized fibrinogen (250 ng per well) for 2 hours at 37°C. Quantification of bound cells was performed as described in the legend to Figure 7. (B) CHO cells expressing the Duva+ form of the complex were incubated with RGDS (open bar) or a control RGES (gray bar) peptides prior to adding 10 μL anti-Duva+ sera corresponding to a half-saturation amount. After a washing, bound human antibodies were detected by flow cytometry as described in the legend to Figure 3. Results represent the mean ± SD of 3 experiments.

Close modal

According to the localization of the Duv polymorphism in the RGD binding domain of GP IIIa, the inhibition of the anti-Duva+antibody binding by the RGDS peptide was analyzed by flow cytometry (Figure 10B). The anti-Duva+ antibody binding was inhibited to 54.7% in the presence of 25 mM RGDS. No significant inhibition was observed with the RGES control peptide in similar experimental conditions.

We report here the characterization of a new platelet alloantigen of low frequency involved in a case of severe neonatal thrombocytopenia. The MAIPA technique revealed a strong selective binding of the maternal serum to the paternal GP IIb-IIIa complex. The serum failed to react with phenotyped platelets from a panel despite a maternofetal incompatibility in the HPA-3 system. Western blot study showed the epitope was localized on the GP IIIa subunit of the platelet GP IIb-IIIa complex. Sequencing analysis of the paternal gene coding for GP IIIa indicated a single base substitution 517C>T (cDNA) in a heterozygous state that resulted in a Thr140Ile polymorphism on mature GP IIIa. The same results were obtained in the child's DNA. Transient expression of the mutated GP IIIa in Cos cells cotransfected with GP IIb did not prevent the GP IIb-IIIa complex from being normally expressed on the cell surface and confirmed this point mutation was sufficient to induce the formation of the epitope recognized by the antibody present in the maternal serum. By using the SSCP technique, the frequency of this new allele was estimated to be less than 1% in our series.

Chymotryptic treatment of GP IIIa resulted in the loss of the reactivity of the anti-Duva+ antibody. Furthermore, the molecular conformation of GP IIIa was important for the expression of the epitope, because disruption of disulfide bonds by DTT treatment impaired the binding of the antibody. This is also the case with the HPA-1a and HPA-4a epitopes where synthetic linear peptides encompassing the antigenic polymorphisms are not recognized by the respective alloantibodies.5,34 As for these other well-characterized alloantibodies,5,35,36 the Thr140Ile polymorphism is necessary, but not sufficient, to express the epitope recognized by the anti-Duva+ antibody.

The effect of the anti-Duva+ antibody on platelet aggregation has not been tested because we were not able to find any Duva+ homozygous platelets. Nevertheless, its ability to impair the binding of CHO cells expressing the Duva+ form of the complex on fibrinogen strongly suggests that it may inhibit platelet aggregation similarly to anti–HPA-4a antibody.37In these conditions attention must be paid to the increased risk of bleeding due to a potential platelet dysfunction induced by the anti-Duva+ antibody. However, it has been difficult to predict hemorrhagic tendency on the basis of the in vitro experiments. Although it has been shown that anti–HPA-1a antibody induces a thrombastheniclike platelet dysfunction of normal HPA-1a platelets regardless of zygosity,38 this was not observed in other reports.37,39 In our case the infant, heterozygous for the Duva+ antigen, did not exhibit any severe bleeding episodes.

The Thr140Ile mutation is localized in a GP IIIa domain shown to be critical for both the surface expression and the function of the complex. Biochemical data on the structural/functional relationship30,40-43 and several amino acid substitutions, observed in patients with Glanzmann phenotypes or obtained by site-directed mutagenesis, stress the importance of this domain of GP IIIa.44-49 The Thr140Ile mutation could alter the local 3-dimensional structure of this GP IIIa domain and affect the adhesive and signaling properties of the integrin. The function of the complex IIb–mutated IIIa was analyzed by using cotransfected CHO stable cell lines. Fibrinogen, as did the ligand mimetic antibody PAC-1, bound the Duva+ allelic form of the complex once activated by DTT. The Thr140Ile substitution did not alter the fixation of the anti-LIBS D328 and the consequent activation of GP IIb-IIIa leading to the binding of PAC-1. CHO cells expressing the Duva+form of the complex can aggregate following activation by DTT and adhere to adsorbed fibrinogen in a dose-dependent manner. The use of the Moab AP-2 or the peptide RGDS as inhibitors confirms the specificity of this adhesion process. Binding of fibrinogen, PAC-1, and RGDS to the Duva+ form of GP IIb-IIIa shows that none of the 2 putative ligand binding sites50 on the complex seemed to be affected by the substitution. Normal cell spreading and pp125FAK phosphorylation show that the Duva+mutation did not affect the outside-in signaling property of the GP IIb-IIIa complex. Our results indicate that the Thr140Ile substitution had little or no effect on either the expression or the function of the GP IIb-IIIa complex. Similar results have been obtained with the Arg143Gln substitution51 that is proximal to the Duv polymophic site.

The 517C>T substitution did not impair HPA-4 genotyping by the PCR–sequence-specific primer technique we used. Moreover, we observed a normal reactivity of an anti–HPA-4a antibody (Pen) with the Duva+ form of GP IIb-IIIa.

To summarize, in the context of severe neonatal thrombocytopenia, we have characterized a new low-frequency antigen carried by platelet GP IIIa. A 517C>T substitution has been shown to result in a Thr140Ile polymorphism. For routine diagnosis, this substitution cannot be detected by the PCR–restriction fragment length polymorphism technique because no known restriction site is created or abolished. A mutation proximal to the Duv substitution has not yet been shown to be associated with the Glanzmann phenotype, and the present study is consistent with this, indicating as it does that the Thr140Ile substitution does not significantly affect the expression or the function of the complex.

The authors thank Drs Peter J. Newmann and Ronggang Wang for the kind gift of the anti–HPA-4a serum and the plasmids pcDNA3-IIb and pcDNA3-IIIa, Dr Lisa Jennings for the kind gift of the Moab D3, and Prof Alan Waters for reading the manuscript. We also thank Mr P. Gane for his technical help in flow cytometry studies.

Supported by a grant from the SESEP (Société d'Etudes et de Soins pour les Enfants Paralysés et Polymalformés), Paris, France.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Hynes
RO
Integrins: versatility, modulation, and signaling in cell adhesion.
Cell.
69
1992
11
25
2
Farrell
DH
Thiagarajan
P
Chung
DW
Davie
EW
Role of fibrinogen α and β chain sites in platelet aggregation.
Proc Natl Acad Sci U S A.
89
1992
10729
10732
3
Liu
Q
Matsueda
G
Brown
E
Frojmovic
M
The AGDV residues on the γ chain carboxyl terminus of platelet-bound fibrinogen are needed for platelet aggregation.
Biochim Biophys Acta.
1343
1997
316
326
4
Newman
PJ
Derbes
RS
Aster
RH
The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing.
J Clin Invest.
83
1989
1778
1781
5
Wang
R
Furihata
K
McFarland
JG
Friedman
K
Aster
RH
Newman
PJ
An amino acid polymorphism within the RGD binding domain of platelet membrane glycoprotein IIIa is responsible for the formation of the Pena/Penb alloantigen system.
J Clin Invest.
90
1992
2038
2043
6
Wang
R
McFarland
JG
Kekomäki
R
Newman
PJ
Amino acid 489 is encoded by a mutational “hot spot” on the β-3 integrin chain: the CA/TU human platelet alloantigen system.
Blood.
82
1993
3386
3391
7
Kuijpers
RWAM
Simsek
S
Faber
NM
Goldschmeding
R
van Wermerkerken
RKV
von dem Borne
AEGKr
Single point mutation in human glycoprotein IIIa is associated with a new platelet-specific alloantigen (Mo) involved in neonatal alloimmune thrombocytopenia.
Blood.
81
1993
70
76
8
Santoso
S
Kalb
R
Kroll
H
et al
A point mutation leads to an unpaired cysteine residue and a molecular weight polymorphism of a functional platelet β3 integrin subunit. The Sra alloantigen system of GPIIIa.
J Biol Chem.
269
1994
8439
8444
9
Peyruchaud
O
Bourre
F
Morel-Kopp
MC
et al
HPA-10wb (Laa): genetic determination of a new platelet specific alloantigen on glycoprotein IIIa and its expression in cos-7 cells.
Blood.
89
1997
2422
2428
10
Simsek
S
Folman
C
van der Schoot
CE
von dem Borne
AEGKr
The Arg633His substitution responsible for the private platelet antigen Groa unravelled by SSCP analysis and direct sequencing.
Br J Haematol.
97
1997
330
335
11
Santoso
S
Pylypiw
R
Wilke
IG
Kroll
H
Kiefel
V
One amino acid deletion of the PLA2 allelic form of GP IIIa leads to the formation of the new platelet alloantigen, Oe(a) [abstract].
Transfus Med.
8
1998
257
12
Lyman
S
Aster
RH
Visentin
GP
Newman
PJ
Polymorphism of human platelet membrane glycoprotein IIb associated with the Baka/Bakb alloantigen system.
Blood.
75
1990
2343
2348
13
Noris
P
Simseck
S
de Bruijne-Admiraal
LG
et al
Maxa, a new low-frequency platelet-specific antigen localized on glycoprotein IIb, is associated with neonatal alloimmune thrombocytopenia.
Blood.
86
1995
1019
1026
14
Kekomäki
S
Raivio
P
Kero
P
A new low-frequency platelet alloantigen, Vaa, on glycoprotein IIbIIIa associated with neonatal alloimmune thrombocytopenia.
Transfus Med.
2
1992
27
33
15
Dreyfus
M
Kaplan
C
Verdy
E
Schlegel
N
Durand-Zaleski
I
Tchernia
G
Frequency of immune thrombocytopenia in newborns: a prospective study. Immune Thrombocytopenia Working Group.
Blood.
89
1997
4402
4406
16
Mueller-Eckhardt
C
Kiefel
V
Grubert
A
et al
348 cases of suspected neonatal allo-immune thrombocytopenia.
Lancet.
1
8634
1989
363
366
17
Kaplan
C
Morel-Kopp
MC
Kroll
H
et al
HPA-5b (Br(a)) neonatal alloimmune thrombocytopenia: clinical and immunological analysis of 39 cases.
Br J Haematol.
78
1991
425
429
18
Santoso
S
Kalb
R
Walka
M
Kiefel
V
Mueller-Eckhardt
C
Newman
PJ
The human platelet alloantigens Bra and Brb are associated with a single amino acid polymorphism on glycoprotein Ia (integrin subunit α2).
J Clin Invest.
92
1993
2427
2432
19
Kiefel
V
Santoso
S
Weisheit
M
Mueller-Eckhardt
C
Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies.
Blood.
70
1987
1722
1726
20
Miller
SA
Dykes
DD
Polesky
HF
A simple salting out procedure for extracting DNA from human nucleated cells.
Nucleic Acids Res.
16
1988
1215
21
Klüter
H
Fehlau
K
Panzer
S
Kirchner
H
Bein
G
Rapid typing for human platelet antigen systems -1, -2, -3 and -5 by PCR amplification with sequence specific primers.
Vox Sang.
71
1996
121
125
22
Kalb
R
Santoso
S
Unkelbach
K
Kiefel
V
Mueller-Eckhardt
C
Localization of the Br polymorphism on a 144 bp exon of the GPIa gene and its application in platelet DNA typing.
Thromb Haemost.
71
1994
651
654
23
Tanaka
S
Taniue
A
Nagao
N
et al
Genotype frequencies of the human platelet antigen, Ca/Tu, in Japanese, determined by a PCR-RFLP method.
Vox Sang.
70
1996
40
44
24
Jallu
V
Diaz-Ricart
M
Ordinas
A
Pico
M
Vezon
G
Nurden
AT
Two human antibodies reacting with different epitopes on integrin β 3 of platelets and endothelial cells.
Eur J Biochem.
222
1994
743
751
25
Quintanar
A
Jallu
V
Legros
Y
Kaplan
C
Human platelet antigen genotyping using a fluorescent SSCP technique with an automatic sequencer.
Br J Haematol.
103
1998
437
444
26
Zimrin
AB
Gidwitz
S
Lord
S
et al
The genomic organization of platelet glycoprotein IIIa.
J Biol Chem.
265
1990
8590
8595
27
Lyman
S
Gilmore
A
Burridge
K
Gidwitz
S
White
GC
II
Integrin-mediated activation of focal adhesion kinase is independent of focal adhesion formation or integrin activation. Studies with activated and inhibitory β3 cytoplasmic domain mutants.
J Biol Chem
272
1997
22538
22547
28
Kouns
WC
Jennings
LK
Activation-independent exposure of the GPIIb-IIIa fibrinogen receptor.
Thromb Res.
63
1991
343
354
29
Schaffner-Reckinger
E
Gouon
V
Melchior
C
Plançon
S
Kieffer
N
Distinct involvement of β3 integrin cytoplasmic domain tyrosine residues 747 and 759 in integrin-mediated cytoskeletal assembly and phosphotyrosine signalling.
J Biol Chem.
273
1998
12623
12632
30
D'Souza
SE
Ginsberg
MH
Burke
TA
Lam
SCT
Plow
EF
Localization of an Arg-Gly-Asp recognition site within an integrin adhesion receptor.
Science.
242
1988
91
93
31
Taub
R
Gould
RJ
Garsky
VM
et al
A monoclonal antibody against the platelet fibrinogen receptor contains a sequence that mimics a receptor recognition domain in fibrinogen.
J Biol Chem.
264
1989
259
265
32
Pidard
D
Montgomery
RR
Bennett
JS
Kunicki
TJ
Interaction of AP-2, a monoclonal antibody specific for the human platelet glycoprotein IIb-IIIa complex, with intact platelets.
J Biol Chem.
258
1983
12582
12586
33
Plow
EF
Pierschbacher
MD
Ruoslahti
E
Marguerie
G
Ginsberg
MH
Arginyl-glycyl-aspartic acid sequences and fibrinogen binding to platelets.
Blood.
70
1987
110
115
34
Flug
F
Espinola
R
Liu
LX
et al
A 13-mer peptide straddling the leucine33/proline33 polymorphism in glycoprotein IIIa does not define the PLA1 epitope.
Blood.
77
1991
1964
1969
35
Valentin
N
Visentin
GP
Newman
PJ
Involvement of the cysteine-rich domain of glycoprotein IIIa in the expression of the human platelet alloantigen, PlA1: evidence for heterogeneity in the humoral response.
Blood.
85
1995
3028
3033
36
Honda
S
Honda
Y
Bauer
B
Ruan
C
Kunicki
TJ
The impact of three-dimensional structure on the expression of PlA alloantigens on human integrin β3.
Blood.
86
1995
234
242
37
Furihata
K
Nugent
DJ
Bissonette
A
Aster
RH
Kunicki
TJ
On the association of the platelet-specific alloantigen, Pena, with glycoprotein IIIa. Evidence for heterogeneity of glycoprotein IIIa.
J Clin Invest.
80
1987
1624
1630
38
van Leeuwen
EF
Leeksma
OC
van Mourik
JA
Engelfriet
CP
von dem Borne
AEGKr
Effect of the binding of anti-Zwa antibodies on platelet function.
Vox Sang.
47
1984
280
289
39
Beadling
WV
Herman
JH
Stuart
MJ
Keashen-Schnell
M
Miller
JL
Fetal bleeding in neonatal alloimmune thrombocytopenia mediated by anti-PlA1 is not associated with inhibition of fibrinogen binding to platelet GP IIb/IIIa.
Am J Clin Pathol.
103
1995
636
641
40
Charo
IF
Nannizzi
L
Phillips
DR
Hsu
MA
Scarbourgh
RM
Inhibition of fibrinogen binding to GP IIb-IIIa by a GP IIIa peptide.
J Biol Chem.
266
1991
1415
1421
41
Tozer
EC
Liddington
RC
Sutcliffe
MJ
Smeeton
AH
Loftus
JC
Ligand binding to integrin αIIbβ3 is dependent on a MIDAS-like domain in the β3 subunit.
J Biol Chem.
271
1996
21978
21984
42
Lin
ECK
Ratnikov
BI
Tsai
PM
et al
Evidence that the integrin β3 and β5 subunits contain a metal ion-dependent adhesion site-like motif but lack an I domain.
J Biol Chem.
272
1997
14236
14243
43
Lin
ECK
Ratnikov
BI
Tsai
PM
et al
Identification of a region in the integrin β3 subunit that confers ligand binding specificity.
J Biol Chem.
272
1997
23912
23920
44
Basani
RB
Brown
DL
Vilaire
G
Bennett
JS
Poncz
M
A Leu117→Trp mutation within the RGD-peptide cross-linking region of β3 results in Glanzmann thrombasthenia by preventing αIIbβ3 export to the platelet surface.
Blood.
90
1997
3082
3088
45
Loftus
JC
O'Toole
TE
Plow
EF
Glass
A
Frelinger
AL
III
Ginsberg
MH
A β3 integrin mutation abolishes ligand binding and alters divalent cation-dependent conformation.
Science.
249
1990
915
918
46
Bajt
ML
Loftus
JC
Mutation of a ligand binding domain of β 3 integrin. Integral role of oxygenated residues in α IIb β 3 (GP IIb-IIIa) receptor function.
J Biol Chem.
269
1994
20913
20919
47
Kouns
WC
Steiner
B
Kunicki
TJ
et al
Activation of the fibrinogen binding site on platelet isolated from a patient with the Strasbourg I variant of Glanzmann's thrombasthenia.
Blood.
84
1994
1106
1115
48
Bajt
ML
Ginsberg
MH
Frelinger
AL
III
Berndt
MC
Loftus
JC
A spontaneous mutation of integrin αIIbβ3 (platelet glycoprotein IIb-IIIa) helps define a ligand binding site.
J Biol Chem.
267
1992
3789
3794
49
Newman
PJ
Weyerbusch-Bottum
S
Visentin
GP
Gidwitz
S
White
GC
II
Type II Glanzmann thrombasthenia due to a destabilizing amino acid substitution in platelet membrane glycoprotein IIIa [abstract].
Thromb Haemost.
69
1993
1017
50
Cierniewski
CS
Byzova
T
Papierak
M
et al
Peptide ligands can bind to distinct sites in integrin αIIbβ3 and elicit different functional responses.
J Biol Chem.
274
1999
16923
16932
51
Wang
R
Newman
PJ
Adhesive and signaling properties of a naturally occurring allele of glycoprotein IIIa with an amino acid substitution within the ligand binding domain—the Pena/Penb platelet alloantigenic epitopes.
Blood.
92
1998
3260
3267

Author notes

C. Kaplan, Laboratoire d'Immunologie Plaquettaire, INTS, 6 rue A. Cabanel, 75 015 Paris, France; e-mail:cecile.kaplan@teaser.fr.

Sign in via your Institution